vaccines - s3-ap-southeast-1.amazonaws.com
TRANSCRIPT
www.informaconnect.com.sg/event/vaccines-therapeutics
Addressing the Need for Speed COVID-19 Trials, BioProcess Development, Manufacturing and Commercialisation
28–30 October 2020 | Delivered Digitally
AND THERAPEUTICS 2020
VACCINES
New in 2020!
Global Outlook for Coronavirus and Other Novel Diseases
Investing and Financing Vaccines and Therapeutics Candidates
Regional Projects, Partnerships and Collaboration Opportunities on Vaccines Development
Boosting Capacity of Large-Scale Vaccine Manufacturing
R&D Innovation and Access to The Newest Technology Available in The Market
Case Studies on Candidate Developments, Including COVID-19
ANDREAS SCHMIDTChief Executive Officer,
Proteona, Germany
SANJAY SINGHChief Executive
Officer, Gennova Biopharmaceuticals, India
MIKE WHELANProject Leader, CEPI,
United Kingdom
WU KEChief Executive Officer,
Bravovax, China
PROF NIKOLAI PETRVSKYResearch Director, Vaxine,
Australia
DR. KUMAR VISVANATHANClinical Director of
Medicine & Emergency Services, Co-Director of
the Immunology Research Centre, St. Vincent’s Hospital Melbourne,
Australia
CHAO SHOUBAIChief Operating Officer, Cansino Therapeutics,
China
ANAND GAUTAMExecutive Director &
Emerging Science Lead APAC, Pfizer, Australia
KAYVON MODJARRADDirector, Emerging Infectious Diseases,
US Military HIV Research Program, United States
JEROME BOYD-KIRKUPChief Scientific Officer,
Hummingbird Bioscience, Singapore
MICHAEL AGREZChief Executive Officer
and Chief Scientific Officer, InterK Peptide
Therapeutics Ltd, Australia
DR. JEAN-LOUIS EXCLERProgram Director,
New Initiatives, International Vaccine Institute, South Korea
DR. KENNETH NOONANChief Executive Officer, Lightstone Singapore,
Singapore
GOPINATH NAGESHWARANStrategy and Planning
Lead, Vaccine Epidemiology and Modelling, Sanofi,
Singapore
DR. TAM C. NGUYENDeputy Director of Research,
St. Vincent’s Hospital Melbourne, Associate
Professor, Melbourne Medical School, Adjunct Associate
Professor (Research), Monash School of Public
Health & Preventive Medicine
PROF DEAN HOProvost’s Chair Professor of
Biomedical Engineering and Pharmacology, Director of The N.1 Institute for Health (N.1), Director of Institute for Digital Medicine (WisDM),
Department Head of Biomedical Engineering, National University
of Singapore, Singapore
www.informaconnect.com.sg/event/vaccines-therapeutics
UNRIVALLED LIST OF VACCINES MANUFACTURERS, RESEARCHERS AND BIOTECHS
DAY ONE: WEDNESDAY 28 OCTOBER 2020
www.informaconnect.com.sg/event/vaccines-therapeutics
GLOBAL MANUFACTURING CAPABILITIES
13:00 Chairperson’s Opening Remarks
13:00 KEYNOTE ADDRESS Global Pharma Partnerships: Improving Production
Technology and Manufacturing Capabilities Safely — Speeding development timeline
— Meeting nimble manufacturing capacity
— Moving from manufacturing to access
— Managing critical supply chain and logistics deliverables
Supply Chain Senior Representative, Johnson and Johnson, Singapore
13:30 CHINA ADDRESS Ramping Up Coronavirus Vaccines Manufacturing
and Speed to Market — Clinical trials update - Progressing in late-stage
— Increasing manufacturing capacity
— Managing regulations and candidate efficacy
— Safety protocol and vigorously monitoring outcomes
— The case of Ad5-nCoV
Chao Shoubai, Chief Operating Officer, Cansino Therapeutics, China
14:00 In Pursuit of COVID-19 Vaccine – Global Alliance, Funding and a Push for Manufacturing
— CEPI’s role in accelerating alliance, partnership, funding and developing safe vaccines
— Overview of COVID-19 investments
— Expanding and enabling manufacturing capabilities
— Ensuring access, affordability and supply
— What can we expect next?
Mike Whelan, Project Leader, CEPI, United Kingdom
14:30 Networking and Stretch Break
15:00 MANUFACTURING PANEL Reaching for Manufacturing Capacity and a Rapid
Scale-up of Production — Cooperation for speed and scale
— Will tech transfer be critical in succeeding COVID-19 production?
— Ensuring that manufacturing is flexible and fungible
— Manufacturing capacity, capability and investment in process and technology
— Vaccine safety and production optimisation
— Manufacturing infrastructure and capacity
Panellists:
Supply Chain Senior Representative, Johnson and Johnson, Singapore
Chao Shoubai, Chief Operating Officer, Cansino Therapeutics, China
Michael Agrez, Chief Executive Officer and Chief Scientific Officer, InterK Peptide Therapeutics Ltd, Australia
ACCELERATING VACCINES DEVELOPMENT
15:50 CASE STUDY Accelerating Development and Optimising
Antibodies Development to Existing Treatments — Managing crisis and opportunities during COVID-19
— How to adapt and adjust antibodies developments
— Overcoming the different risks for vaccines
Andreas Schmidt, Chief Executive Officer, Proteona, Germany
16:20 CASE STUDY Developing Therapeutic Antibodies Using Rational
Antibody Discovery — Overview of the therapeutic antibody discovery landscape
— Challenges of classical approaches to monoclonal antibodies (mAb) discovery
— Major benefits of Hummingbird’s approach using its proprietary rational antibody discovery (RAD) platform
— Successes in developing antibodies recognizing precise epitopes on both HER3 and VISTA
Jerome Boyd-Kirkup, Chief Scientific Officer, Hummingbird Bioscience, Singapore
16:50 Upscaling Vaccines Manufacturing Process For speaking enquiry, please contact
17:20 Peptides as Therapeutic and Vaccine Adjuvants in Combating COVID-19
— Modulation of kinase activity
— Th1-skewed immune-boosting response
— Immune dysfunction in the elderly
— Memory cells
Michael Agrez, Chief Executive Officer and Chief Scientific Officer, InterK Peptide Therapeutics Ltd, Australia
18:00 Chairperson’s Summary and End of Day 1
DAY TWO: THURSDAY 29 OCTOBER 2020
www.informaconnect.com.sg/event/vaccines-therapeutics
R&D INNOVATE
13:00 Chairperson’s Opening Remarks
13:00 AUSTRALIAN CASE STUDY Reengineering Existing CoV Candidates for
COVID-19 Vaccines Development — Adapting AI into vaccine development — Tapping on recombinant spike protein
Prof Nikolai Petrvsky, Research Director, Vaxine, Australia
13:30 Effective Vaccine Formulation and Process Development
For speaking enquiry, please contact [email protected]
14:00 CASE STUDY Nanoparticle SARS-CoV-2 Vaccine Development
— Potential of tackling viral diversities — Data collection for safety and efficacy — Ensuring rapid scalability of candidate
Kayvon Modjarrad, Director, Emerging Infectious Diseases, US Military HIV Research Program, United States
14:30 Online Networking and Stretch Break
15:00 The Future is Now: The Role of AI in the Combat with COVID-19
— Collaborating technology in search of cures — How AI has been leveraged in the search for optimal drug combinations to treat COVID-19 patients
— How does IDentif.AI platform make precise recommendations based on dosage and mix
— Key process implementations and what are the challenges faced
— Success rate and key takeaways Prof Dean Ho, Provost’s Chair Professor of Biomedical
Engineering and Pharmacology, Director of The N.1 Institute for Health (N.1), Director of Institute for Digital Medicine (WisDM), Department Head of Biomedical Engineering, National University of Singapore, Singapore
VACCINES TRIALS AND COVID-19
15:30 THE GLOBAL DIALOGUE Reimagining Drug Discovery in The Face of
COVID-19 and Current State of Treatment Trials — What are the key priorities for different region’s global race for COVID-19 vaccine development?
— Government role in trials approval and funding support
— Using adaptive trial design to fast track clinical programs
— The collaboration between countries / institutions on COVID vaccine trials
Panelists:
Dr. Jean-Louis Excler, Program Director, New Initiatives, International Vaccine Institute, South Korea
Dr. Kumar Visvanathan, Clinical Director of Medicine & Emergency Services, Co-Director of the Immunology Research Centre, St. Vincent’s Hospital Melbourne, Australia
Dr. Tam C. Nguyen, Deputy Director of Research, St. Vincent’s Hospital Melbourne, Associate Professor, Melbourne Medical School, Adjunct Associate Professor (Research), Monash School of Public Health & Preventive Medicine, Australia
16:20 INDIA’S CASE STUDY Tackling COVID-19 with Nanotechnology and
mRNA — Accelerating clinical trials
— From India to the rest of the world
— Upscaling production of candidate
Sanjay Singh, Chief Executive Officer, Gennova Biopharmaceuticals, India
16:50 Evidence Generation for Vaccine Safety and Efficacy — Effective evidence generation strategies
— Expediting candidate approval processes
— Correcting misinformation for vaccine use through evidence
Gopinath Nageshwaran, Strategy and Planning Lead, Vaccine Epidemiology and Modelling, Sanofi, Singapore
17:20 Capitalising on Big Data for Better Clinical Outcomes to Speed Up Access for Patients
— Optimising R&D efficiency and speeding up access to patients through big data
— Effective use of big data analytics and how it helps to learn about the virus progresses among diverse patient populations
— What is the paradigm shift towards value and outcomes in the healthcare and pharma system?
Dr. Tam C. Nguyen, Deputy Director of Research, St. Vincent’s Hospital Melbourne, Associate Professor, Melbourne Medical School, Adjunct Associate Professor (Research), Monash School of Public Health & Preventive Medicine, Australia
18:00 Chairperson’s Summary and End of Day 2
PARTNERSHIPS AND ALLIANCES
13:00 Chairperson’s Opening Remarks
Mike Whelan, Project Leader, CEPI, United Kingdom
13:00 Investor’s Perspective: Assessing the Immunology and Antibodies Market
— Investors’ evolving expectations
— Understanding operational capabilities for value proposition
— Managing portfolio investments
Dr. Kenneth Noonan, Chief Executive Officer, Lightstone Singapore, Singapore
13:30 CASE STUDY International Collaboration for Vaccines
Development — Balancing HIV and COVID candidate’s development
— International data sharing to bridge knowledge gap
— Working together for vaccines deployment
Dr. Jean-Louis Excler, Program Director, New Initiatives, International Vaccine Institute, South Korea
14:00 Partnering for Meaningful Innovation — Innovation and developing cancer vaccines
— Collaboration for Agile Pharma
— Expanding pipelines and technology
Anand Gautam, Executive Director & Emerging Science Lead APAC, Pfizer, Australia
14:30 Online Networking and Stretch Break
15:00 Vaccines Packaging, Distribution, and Storage For speaking opportunities, contact
15:30 Preparing the Supply Chain for Coronavirus Vaccines
— Supply meeting demand: How to ensure sufficient supplies for the world
— Strategies to improve operational efficiency for supply chain
— Optimising vaccine distribution for the public
— Collaboration with stakeholders for speedy vaccines production
Panelists:
Michael Agrez, Chief Executive Officer and Chief Scientific Officer, InterK Peptide Therapeutics Ltd, Australia
Chao Shoubai, Chief Operating Officer, Cansino Therapeutics, China
Wu Ke, Chief Executive Officer, Bravovax, China More panelists to be confirmed
16:15 Strategic Alliances for Production, Procurement and Distribution of Vaccines
— Critical procurement decision-making
— Advancements in technology and R&D
— Coordinating with international bodies for vaccines supply security
— Working away from inward policy trends for better vaccines distribution
Moderator:
Mike Whelan, Project Leader, CEPI, United Kingdom Panelists:
Andreas Schmidt, Chief Executive Officer, Proteona, Germany
Anand Gautam, Executive Director & Emerging Science Lead APAC, Pfizer, Australia
More panelists to be confirmed
17:00 Chairperson’s Summary and End of Day 3
DAY THREE: FRIDAY 30 OCTOBER 2020
www.informaconnect.com.sg/event/vaccines-therapeutics
Get insights from regional vaccines developers and manufacturers alike as they share market updates, case studies and their thought leadership on key issues such as current vaccines candidacy analysis, R&D and trials insights, private sector investment showcases, government grants and incentives, outlines strategies to scaling up manufacturing and centre staging technological advancements. There will also be focus on vaccines safety, speed to market, affordability, and commercial viability that are pivotal part of vaccine development and delivery.
PARTNERSHIP OPPORTUNITIES AVAILABLEFor more information about how you can leverage on our platform and optimise your marketing budget to reach your target audience, please contact:
Yvonne Leong
Tel: +65 9852 3283 | Email: [email protected]
ABOUT VACCINES AND THERAPEUTICS
WHY ATTEND A DIGITAL EVENT?
WHO WILL YOU MEET?
www.informaconnect.com.sg/event/vaccines-therapeutics
BY INDUSTRY BY GEOGRAPHY
Pharma & Biotechs
Others
Scientific Reserach& Universities
Regulators, Healthcare Agencies & Associations
CDMO/CROs/CMOs
Tech Solution ProvidersEurope
North Asia
Australia
USA
Other Regions
ASEAN
India
NETWORKING | Connect instantly with full visibility of the participant list via our secure and unique match making platform accessible to all participants, and integrated with the virtual conference.
KNOWLEDGE AND ENGAGEMENT | Same content, but more interactive. Even more opportunities to reach out to fellow participants and speakers using specific tools in our virtual conference platform.
FOCUSED AND TIMELY LEARNING | Receive the latest and most timely trends and figures from leading industry players at your convenience.
CONVENIENCE | With our On Demand Webcasts you can participate from any location, better plan your time and watch what you missed whenever you want.
TIME-EFFICIENT AND COST-SAVING | Save valuable time and money on travelling and accommodation.
REGISTRATIONREGISTER WITH YOUR TEAMS TO ATTEND AND ENJOY
SPECIAL GROUP RATES!
CLICK HERE TO FIND OUT MORE
AND THERAPEUTICS 2020
VACCINESEARLY BIRD RATE
Register & Pay by 4 Sep 2020STANDARD RATE
Register & Pay after 4 Sep 2020
Live Online Experience – Pharma, Biotech Companies Rate SGD $1,595 SGD $1,795
Live Online Experience – Industry Rate SGD $1,895 SGD $2,095
Start-Up Rate SGD $495
GROUP RATE (Per delegate)
PHARMA, BIOTECH COMPANIES RATE
Group of 3 or more SGD $1,195 SGD $1,295
Group of 5 or more SGD $695 SGD $795
Group of 10 or more SGD $395 SGD $495
INDUSTRY RATE
Group of 3 or more SGD $1,295 SGD $1,495
Group of 5 or more SGD $995 SGD $1,095
Group of 10 or more SGD $695 SGD $795
SPECIAL CORPORATE RATE STANDARD RATE
Register 25 Passes SGD $5,750
Register 50 Passes SGD $8,995
For terms and conditions, refer to www.informaconnect.com.sg/terms/
FOR GROUP REGISTRATIONS, PLEASE EMAIL [email protected] OR CALL +65 6508 2477
3 EASY WAYS TO REGISTERContact Miki Kong
+65 6508 2477
Registration Enquiry Email
Website
www.informaconnect.com.sg/event/vaccines-therapeutics
REGISTER NOW
www.informaconnect.com.sg/event/vaccines-therapeutics